Table 5 Risk of VTE in patients with different T2DM durations

Last HbA1c: 0–5 y since T2DM diagnosis

 ≤ 6.5% (≤ 48 mmol/mol)

446 (33.7)

2042 (38.6)

1.02 (0.86–1.20)

1.06 (0.89–1.25)

 > 6.5–7.0% (> 48–53 mmol/mol)

210 (15.9)

990 (18.7)

1 (reference)

1 (reference)

 > 7.0–7.5% (> 53–58 mmol/mol)

172 (13.0)

651 (12.3)

1.24 (1.01–1.51)

1.20 (0.97–1.49)

 > 7.5–8.0% (> 58–64 mmol/mol)

86 (6.5)

326 (6.2)

1.30 (1.01–1.68)

1.29 (1.00–1.67)

 > 8.0–9.0% (> 64–75 mmol/mol)

104 (7.9)

336 (6.4)

1.51 (1.20–1.91)

1.44 (1.13–1.83)

 > 9.0% (> 75 mmol/mol))

114 (8.6)

348 (6.6)

1.61 (1.27–2.03)

1.39 (1.07–1.79)

 No Recording

191 (14.4)

596 (11.3)

1.75 (1.40–2.19)

1.78 (1.41–2.24)

Last HbA1c: 5–10 y since T2DM diagnosis

 ≤ 6.5% (≤ 48 mmol/mol)

260 (32.1)

1168 (35.8)

0.84 (0.69–1.02)

0.83 (0.68–1.01)

 > 6.5–7.0% (> 48–53 mmol/mol)

161 (19.9)

618 (19.0)

1 (reference)

1 (reference)

 > 7.0–7.5% (> 53–58 mmol/mol)

138 (17.1)

525 (16.1)

1.00 (0.80–1.27)

0.97 (0.76–1.23)

 > 7.5–8.0% (> 58–64 mmol/mol)

58 (7.2)

284 (8.7)

0.78 (0.58–1.05)

0.73 (0.53–1.01)

 > 8.0–9.0% (> 64–75 mmol/mol)

80 (9.9)

270 (8.3)

1.19 (0.90–1.57)

1.11 (0.83–1.48)

 > 9.0% (> 75 mmol/mol))

85 (10.5)

306 (9.4)

1.07 (0.81–1.40)

0.87 (0.65–1.16)

 No Recording

27 (3.3)

88 (2.7)

1.24 (0.81–1.91)

1.46 (0.93–2.31)

Last HbA1c: > 10 y since T2DM diagnosis

 ≤ 6.5% (≤ 48 mmol/mol)

137 (26.3)

599 (29.0)

1.16 (0.87–1.55)

1.10 (0.81–1.48)

 > 6.5–7.0% (> 48–53 mmol/mol)

70 (13.4)

355 (17.2)

1 (reference)

1 (reference)

 > 7.0–7.5% (> 53–58 mmol/mol)

87 (16.7)

346 (16.8)

1.29 (0.95–1.76)

1.20 (0.87–1.64)

 > 7.5–8.0% (> 58–64 mmol/mol)

64 (12.3)

229 (11.1)

1.42 (1.00–2.02)

1.36 (0.94–1.96)

 > 8.0–9.0% (> 64–75 mmol/mol)

69 (13.2)

228 (11.1)

1.53 (1.10–2.14)

1.40 (0.98–1.99)

 > 9.0% (> 75 mmol/mol))

90 (17.3)

275 (13.3)

1.74 (1.26–2.40)

1.33 (0.92–1.91)

No Recording

4 (0.8)

32 (1.6)

0.56 (0.23–1.37)

0.58 (0.22–1.52)